Tag: Bharat Biotech

 Intranasal Covid Vaccine
DCGI nod to Bharat Biotech's intranasal Covid vaccine for restricted emergency use

This step will further strengthen our collective fight against the pandemic, said Union Health Minister Mansukh Mandaviya.

  • Tuesday, 06 September 2022
COVID-19 intranasal vaccine Phase III trials over, proven safe, says Bharat Biotech
COVID-19 intranasal vaccine Phase III trials over, proven safe, says Bharat Biotech

The Centre partially funded product development and clinical trials through the Department of Biotechnology's, COVID Suraksha programme.

  • Monday, 15 August 2022
CEPI partners with Bharat Biotech, others to develop variant-proof Covid vaccine
CEPI partners with Bharat Biotech, others to develop variant-proof Covid vaccine

The CEPI will fund the researchers to conduct activities including immunogen design, preclinical studies, manufacturing process development, and a Phase 1 clinical trial.

  • Wednesday, 11 May 2022
Bharat Biotech UpgraBharat Biotech Upgrading Facilitding Facilities As WHO Suspends Covaxin Supplies
Bharat Biotech Upgrading Facilities As WHO Suspends Covaxin Supplies

The WHO said in a statement late on on Saturday that the Covaxin suspension was in response to the outcomes of its post EUL (emergency use authorisation) inspection, held between March 14-22, and the need to conduct process and facility upgrades to address recently identified GMP (good manufacturing practice) deficiencies.

  • Sunday, 03 April 2022
WHO
WHO Suspends Covaxin Supply To UN Agencies

Bharat Biotech on April 1 announced the temporary slowing down of production of its covid-19 vaccine Covaxin across its manufacturing facilities, having completed its supply obligations to procurement agencies and foreseeing the decrease in demand.

  • Sunday, 03 April 2022
Bharat Biotech's Covaxin
Bharat Biotech Announces Slowing Down Of Covaxin Production

Hyderabad-based vaccine manufacturer Bharat Biotech on Friday announced the temporary slowing down of its Covid vaccine Covaxin's production across its manufacturing facilities.

  • Saturday, 02 April 2022
Nasal Vaccine
Bharat Biotech Gets Nod For COVID-19 Intra-Nasal Vaccine Phase-3 Trials

Bharat Biotech has received approval from the Drug Controller General of India to conduct phase-3 trials for its COVID-19 intra-nasal vaccine (BBV154), sources in the company said on Friday.

  • Friday, 28 January 2022
Bharat Biotech's Krishna Ella
Couple Behind India's Indigenous Covid Vaccine Gets Padma Bhushan

Dr Krishna Ella and Suchitra Ella, the couple behind Bharat Biotech, which developed India's first indigenous vaccine for Covid-19, have been awarded Padma Bhushan, the third highest civilian award in the country.

  • Tuesday, 25 January 2022
BOOSTER WORKING
COVAXIN Booster Dose Data Shows Promising Results

COVAXIN Booster Dose Data Shows Promising Results

Video Icon
  • Wednesday, 12 January 2022
Ensure Availability Of Covaxin If Mixed Match Policy For Booster Is Adopted: IMA
No Painkillers Or Paracetamol Recommended After Covaxin Jab: Bharat Biotech

"Through our clinical trials spanning 30,000 individuals, approximately 10-20 per cent individuals report side effects. Most of these are mild, resolve within 1-2 days, and do not require medication. Medication is only recommended only after you consult a physician," the company said.

  • Wednesday, 05 January 2022
Phase III Trial Of Bharat Biotech Intranasal Vaccine
DGCI Approves For Phase III Trial Of Bharat Biotech Intranasal Vaccine As Booster

According to a source, Bharat Biotech aims to conduct clinical trials on 5,000 healthy subjects: half or 2,500 individuals who have received Covishield and another 2,500 who have been administered Covaxin.

  • Wednesday, 05 January 2022
Covaxin For Children Proven To Be Safe In Paediatric Subjects In Study: Bharat Biotech
Covaxin For Children Proven To Be Safe In Paediatric Subjects In Study: Bharat Biotech

No serious adverse event was reported. 374 subjects reported either mild or moderate severity symptoms with 78.6 per cent getting resolved within one day.

  • Thursday, 30 December 2021
Tesla In-Car Video Games Raise Drivers Safety Concerns
Tesla In-Car Video Games Raise Drivers Safety Concerns

"It is a big concern if it plays in view of the driver, for sure," Jonathan Adkins, executive director of the Governors Highway Safety Association, which coordinates state efforts to promote safe driving, was quoted as saying.

  • Thursday, 09 December 2021
 Covaxin
Covaxin 77.8% Effective Against COVID-19: Lancet study

The phase 3 trial Efficacy and Safety Study involving 25,800 volunteers across 25 sites in India is India's largest ever clinical trial conducted for a Covid-19 vaccine.

  • Friday, 12 November 2021
Bharat Biotech's US Partner Ocugen Seeks Covaxin Approval For Kids
Bharat Biotech's US Partner Ocugen Seeks Covaxin Approval For Kids

Covaxin uses the same Vero Cell manufacturing platform as other childhood vaccines, including the inactivated polio vaccine.

  • Saturday, 06 November 2021
scrollToTop